Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers

Next Previous
Trial Profile

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YE-NEO-001 (Primary)
  • Indications HER2 negative breast cancer; HER2 positive breast cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms QUILT-2.025 NANT
  • Sponsors NantBioScience

Most Recent Events

  • 22 Jun 2023 Planned End Date changed from 30 Dec 2020 to 30 Dec 2025.
  • 22 Jun 2023 Planned primary completion date changed from 30 Dec 2019 to 15 Jul 2025.
  • 22 Jun 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top